Tandem Diabetes Care | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Abbott USD 2.91B 21M 2024-12
Align Technology USD 424.97M 9.17M 2024-12
AtriCure USD 72.18M 1.05M 2024-12
Baxter International USD 615M 16M 2024-12
Becton, Dickinson and Co. USD 1.32B 62M 2024-12
Boston Scientific USD 1.61B 50M 2024-12
Cooper Companies USD 387.9M 3.5M 2025-01
Dexcom USD 327.4M 21M 2024-12
Edwards Lifesciences USD 491.9M 70.5M 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Globus Medical USD 253.48M 12.74M 2024-12
ICU Medical USD 158.54M 3.88M 2024-12
Insulet USD 261M 26.9M 2024-12
Integra LifeSciences USD 169.62M 5.48M 2024-12
Intuitive Surgical USD 612.6M 102M 2024-12
J&J USD 6.45B 975M 2024-12
Masimo USD 223.4M 38.6M 2024-12
Medtronic USD 2.72B 34M 2025-01
Merit Medical Systems USD 102.57M 2.93M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Stryker USD 2.03B 229M 2024-12
Tandem Diabetes Care USD 105.84M 6.2M 2024-12
Teleflex USD 254.55M 7.3M 2024-12
Zimmer Biomet Holdings USD 724.7M 18.8M 2024-12



Tandem Diabetes Care Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.